Skip to content

Zymeworks ZYME Asset turnover

Asset turnover at other companies

Pfizer logo
PfizerPFE
0.3×0.0×
Amgen logo
AmgenAMGN
0.4×0.0×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
0.6×+0.3×
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
0.1×+0.1×
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
0.1×0.0×
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
0.1×-0.5×

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Calculated from Zymeworks’s reported figures.

Based on trailing twelve months.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's asset turnover?
Zymeworks (ZYME) reported asset turnover of 0.2× in Q1 2026.
How has Zymeworks's asset turnover changed year-over-year?
Zymeworks's asset turnover decreased by 5.7% year-over-year, from 0.2× to 0.2×.
What is the long-term trend for Zymeworks's asset turnover?
Over 3 years (2022 to 2025), Zymeworks's asset turnover has grown at a -30.9% compound annual growth rate (CAGR), from 0.8× to 0.3×.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.